PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
树突状细胞代谢：改善抗肿瘤 DC 疫苗的战略路径
英文原题：Dendritic cells metabolism: a strategic path to improve antitumoral DC vaccination.
查看英文原题
Dendritic cells metabolism: a strategic path to improve antitumoral DC vaccination.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
树突状细胞（DC）在免疫应答协调中发挥关键作用，因此被用于多种治疗策略，作为潜在疫苗工具。多项临床试验正在不同实体瘤中研究DC的作用。然而，人们尚未充分了解DC代谢通路对DC疫苗有效性的潜在影响。本综述探讨代谢如何成为DC疫苗制备的关键组成部分，并分析改善以下方面的机会：（i）肿瘤抗原加工及交叉呈递；（ii）DC迁移；（iii）DC免疫原性特征。作者希望借此开启讨论，探索将DC代谢视为抗肿瘤DC疫苗核心组成部分的新方向。
展开英文摘要原文
The critical role developed by dendritic cell (DC) in the orchestration of immune response explains its exploitation in different therapeutic approaches as potential vaccine tools. Various clinical trials dissect its role in different types of solid cancers.
However, there is a lack of comprehension regarding the potential impact of DC metabolic pathways on the effectiveness of DC vaccine. In this review, we intend to dissect how metabolism could be a critical component of DC vaccine formulation, exploring opportunities to improve: (i) processing and cross-presentation of tumour antigens; (ii) DC migration, and (iii) DC immunogenic profile.
Overall, we aim to open the discussion to explore new avenues/paths where DC metabolism might be considered a core component of antitumour DC vaccine with this review.
论文信息
- 作者
- Currivan E、Finlay D、Moreira D
- 单位
- School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse Street, Dublin, 2, Ireland.Ireland
- 文献类型
- 非美国政府资助研究
- 期刊
- Clinical and experimental immunology2022 Jun 11
- 原文标识
- PubMed 35537194 · DOI 10.1093/cei/uxac048